Markers of Osteoporosis in Cystic Fibrosis
University of Texas Southwestern Medical Center
Summary
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return for repeat DEXA scans, micro CT, blood collection, and documenting of any adverse events.
Eligibility
- Age range
- 18–64 years
- Sex
- All
- Healthy volunteers
- Yes
Cystic Fibrosis Main Study Inclusion Criteria: * Must have CF diagnosis confirmed by sweat test or genotype analysis * Subjects (and parents/legal guardians as applicable) must have the ability to read and write in English Sub-study Exclusion Criteria: * No CF diagnosis * Men or women without osteoporosis * Less than 18 years of age * Unwilling to return annually for study visits for up to 5 years * Unwilling and/or medically unable to take denosumab
Interventions
- DrugDenosumab
treatment with denosumab every 6 months for up to 5 years
Location
- UT Southwestern Medical CenterDallas, Texas